Gilead Sciences, Inc.
- Open
- 144.23
- Day high
- 147.22
- Day low
- 143.19
- Prev close
- 145.68
- Volume
- 6.4M
- Mkt cap
- $181.5B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 15.3
- P/S
- 6.0
- Yield
- 1.12%
- Per share
- $1.64
- ▼Insiders net selling -$13.0M over the last 3 months (0 open-market buys, 23 sales)
- 🏛Institutions mixed (13F)
Gilead Sciences, Inc. (GILD) is a Healthcare company listed on NASDAQ. The stock is up 30% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 23 sales (SEC Form 4). Drillr has 3 published research articles covering GILD.
Gilead Sciences, Inc. (GILD) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 8 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GILD earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 4, 2026 | $-7.25 | $-6.75 | +6.9% | $7.8B | +5.5% |
| May 7, 2026 | $1.91 | $2.03 | +6.3% | $7.0B | +0.7% |
| Oct 30, 2025 | $2.13 | $2.47 | +16.0% | $7.8B | +4.3% |
| Aug 7, 2025 | $1.96 | $2.01 | +2.6% | $7.1B | +1.4% |
| Apr 24, 2025 | $1.78 | $1.81 | +1.7% | $6.7B | -2.1% |
| Feb 11, 2025 | $1.74 | $1.90 | +9.2% | $7.6B | +5.8% |
| Aug 8, 2024 | $1.61 | $2.01 | +24.8% | $6.9B | +3.7% |
| Apr 25, 2024 | $-1.49 | $-1.32 | +11.4% | $6.7B | +5.2% |
| Aug 3, 2023 | $1.60 | $1.34 | -16.0% | $6.6B | +2.4% |
| Apr 27, 2023 | $1.64 | $1.37 | -16.5% | $6.4B | -1.7% |
| Feb 2, 2023 | $1.48 | $1.67 | +12.8% | $7.4B | +10.9% |
| Oct 27, 2022 | $1.44 | $1.90 | +31.9% | $7.0B | +14.9% |
GILD insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 27, 2026 | WELTERS ANTHONYdirector | Sell | 3,118 | $148.31 |
| Aug 27, 2026 | WELTERS ANTHONYdirector | Sell | 6,880 | $148.82 |
| Aug 27, 2026 | WELTERS ANTHONYdirector | Option | 7,718 | $60.67 |
| Aug 27, 2026 | WELTERS ANTHONYdirector | Sell | 4,600 | $148.82 |
| Aug 27, 2026 | WELTERS ANTHONYdirector | Sell | 3,402 | $148.24 |
| Aug 27, 2026 | WELTERS ANTHONYdirector | Option | 10,282 | $61.35 |
| Aug 21, 2026 | Bluestone Jeffreydirector | Option | 1,658 | $67.45 |
| Aug 21, 2026 | Bluestone Jeffreydirector | Option | 26 | $67.45 |
| Aug 21, 2026 | Bluestone Jeffreydirector | Sell | 335 | $146.26 |
| Aug 21, 2026 | Bluestone Jeffreydirector | Sell | 1,658 | $145.73 |
| Aug 21, 2026 | Bluestone Jeffreydirector | Option | 1,816 | $67.45 |
| Aug 21, 2026 | Bluestone Jeffreydirector | Option | 1,165 | $67.45 |
| Aug 21, 2026 | Bluestone Jeffreydirector | Option | 335 | $61.35 |
| Aug 21, 2026 | Bluestone Jeffreydirector | Sell | 1,165 | $143.75 |
| Aug 21, 2026 | Bluestone Jeffreydirector | Sell | 1,816 | $144.92 |
Source: GILD SEC Form 4 filings, latest Aug 27, 2026. For informational purposes only — not investment advice.
See the full GILD insider & 13F page →GILD research & analysis
LLY: $2.3B Ajax Buy Hedges Mounjaro Patent Cliff
Eli Lilly's $2.3 billion Ajax Therapeutics acquisition reveals a critical divergence in large-cap pharma M&A strategy that the market has mispriced. While Merck and Pfizer scramble to replace patent cliff revenue with expensive blockbuster acquisitions, Lilly is buying rare-disease optionality from a position of GLP-1 strength. Long LLY versus short MRK/PFE targets 8-12% relative return over six months as earnings reveal the cost of desperate dealmaking.
LLYMRKPFEGILD's $5B Tubulis Deal: Oncology ADC Bet as HIV Growth Slows — Undervalued or Overpaid?
Gilead's $5B Tubulis acquisition on April 9, 2026, targets oncology ADCs to complement HIV strength, backed by $9.5B FCF and undervalued multiples. Shares edged up 0.75% amid pipeline promise, but clinical success is key to unlocking upside.
GILD's $5B Tubulis Deal: Can This Acquisition Finally Unlock Its Oncology Turnaround?
Gilead's $5B Tubulis acquisition announced April 7, 2026, targets ADC tech to bolster oncology amid HIV strength. Solid finances support close, but regulatory and execution risks linger. Bullish for pipeline diversification and undervalued stock.
Gilead Sciences, Inc. company profile
Overview
Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company founded in 1987 and headquartered in Foster City, California. The company went public in 1992 and has established itself as a major player in the pharmaceutical industry, particularly known for its groundbreaking treatments in HIV/AIDS, hepatitis, and oncology. Gilead has built its reputation through innovative drug discovery and development, with a focus on addressing unmet medical needs in serious diseases. The company operates globally, serving patients in the United States, Europe, and international markets through its comprehensive portfolio of specialized medicines.
Business
Gilead Sciences operates as a biopharmaceutical company that discovers, develops, and commercializes prescription medicines for serious diseases. The company focuses on three primary therapeutic areas that represent distinct business segments. HIV/AIDS Treatment and Prevention represents Gilead's largest revenue segment, accounting for approximately 68% of total product sales ($19.6 billion in 2024). This segment includes flagship products like Biktarvy, a once-daily oral tablet that combines three HIV medicines into a single pill for treatment of HIV-1 infection. Biktarvy has become the market leader with 50% U.S. market share. Other HIV products include Descovy for pre-exposure prophylaxis (PrEP) to prevent HIV infection, and legacy treatments like Truvada and Genvoya. The company is preparing to launch lenacapavir, a revolutionary twice-yearly injectable HIV prevention therapy that showed 100% efficacy in clinical trials. Oncology and Cell Therapy comprises roughly 12% of product sales ($3.3 billion in 2024). This segment includes Trodelvy, an antibody-drug conjugate for treating certain types of breast and bladder cancers, and cell therapy products like Yescarta and Tecartus, which are CAR-T cell therapies that genetically modify a patient's own immune cells to fight blood cancers like lymphoma and leukemia. These therapies represent cutting-edge personalized medicine approaches where each treatment is individually manufactured for each patient. Liver Disease Treatment accounts for about 10% of sales ($3 billion in 2024), featuring products like Epclusa and Harvoni for hepatitis C treatment, Vemlidy for chronic hepatitis B, and the newly launched Livdelzi for primary biliary cholangitis, a rare autoimmune liver disease. The company also markets Veklury (remdesivir), an antiviral treatment for COVID-19, though sales have declined significantly as the pandemic has subsided.
Revenue model
Gilead generates revenue primarily through direct product sales of prescription pharmaceuticals to healthcare providers, hospitals, and specialty pharmacies. The company operates under a traditional pharmaceutical business model where it invests heavily in research and development to create innovative medicines, obtains regulatory approval, and then sells these products at premium prices during the patent protection period. The company's revenue streams are geographically diversified, with significant sales in the United States (approximately 70% of revenue) and international markets including Europe and other regions. Pricing varies significantly by geography, with higher prices typically achieved in developed markets like the U.S. due to stronger intellectual property protection and reimbursement systems. Several factors influence Gilead's profitability and margins. Patent exclusivity is crucial - the company enjoys strong pricing power while patents are active, but faces dramatic revenue declines when generic competition enters. Fortunately, Gilead has no major patent expirations until late 2033. Regulatory approval timelines significantly impact revenue potential, as delays can cost millions in lost sales. Healthcare reimbursement policies affect demand, particularly changes like the Medicare Part D redesign which is expected to keep HIV sales flat in 2025 despite underlying demand growth. Competition from both innovative therapies and biosimilars pressures margins, especially in the cell therapy space where Gilead faces competition from bispecific antibodies that offer simpler treatment approaches. Manufacturing complexity particularly affects the cell therapy business, where each treatment must be individually manufactured for each patient, limiting scalability. Research and development costs remain substantial, with the company running 54 ongoing clinical programs, requiring significant upfront investment with uncertain returns.
Competitive moat
Gilead possesses a moderate to strong competitive moat built primarily on its deep expertise in antiviral drug development and established market positions in specialized therapeutic areas. The company's strongest moat exists in HIV treatment, where it has developed a comprehensive portfolio of innovative medicines and maintains significant market share through continuous innovation. Biktarvy's 50% U.S. market share and the upcoming lenacapavir launch for HIV prevention demonstrate the company's ability to maintain leadership through superior drug development capabilities. The company's research and development expertise in virology represents a significant competitive advantage, with decades of experience in developing complex antiviral therapies that require deep scientific understanding. This expertise creates barriers for competitors who lack similar knowledge bases. Additionally, Gilead's established relationships with healthcare providers, payers, and regulatory agencies provide advantages in bringing new products to market efficiently. However, Gilead's moat faces several challenges. In oncology, the company competes against much larger pharmaceutical companies with deeper resources and broader pipelines. The cell therapy business faces particular pressure from bispecific antibodies, which offer simpler administration and manufacturing compared to personalized CAR-T therapies. The patent cliff risk, while delayed until 2033, remains a long-term concern that could significantly impact the HIV franchise. The company's moat is also limited by the regulatory nature of pharmaceutical markets, where even strong market positions can be disrupted by breakthrough therapies from competitors. Generic competition eventually erodes all pharmaceutical moats once patents expire, making continuous innovation essential for maintaining competitive advantages.
Risks & safety
Gilead demonstrates a strong margin of safety with solid financial fundamentals and manageable risk levels. • Cash and liquidity: $7.9 billion in cash and short-term investments as of Q1 2025, providing substantial financial flexibility • Debt management: Debt-to-equity ratio of 1.30, indicating moderate leverage that is manageable given strong cash flows • Cash generation: Strong free cash flow of $1.65 billion in Q1 2025, demonstrating ability to self-fund operations and growth • Solvency: Current ratio of 1.37 indicates adequate short-term liquidity to meet obligations • Valuation metrics: Trading at 26.5x P/E ratio, which appears reasonable given growth prospects and market position • EV/EBITDA: 15.0x suggests moderate valuation relative to earnings power • Patent protection: No major patent expirations until late 2033 provides revenue visibility and reduces near-term competitive risk • Diversification: Revenue spread across multiple therapeutic areas and geographic markets reduces concentration risk • Regulatory risk: Well-established company with strong regulatory track record minimizes approval risks for pipeline products
Recent development
Over the past few years, Gilead has executed a significant strategic transformation focused on expanding beyond its HIV franchise into oncology and preparing for the next generation of HIV treatments. The company's most significant development has been the advancement of lenacapavir, a revolutionary HIV prevention therapy that requires only twice-yearly injections and demonstrated 100% efficacy in preventing HIV infection in clinical trials. The FDA decision is expected by June 2025, with launch anticipated in summer 2025. In oncology, Gilead has been building its portfolio through both internal development and acquisitions. Trodelvy has become a cornerstone asset, showing promising results across multiple cancer types including triple-negative breast cancer and lung cancer. The company is advancing anito-cel, a next-generation CAR-T therapy for multiple myeloma that has shown promising early results without the delayed neurotoxicity issues that affect some competing therapies. The company launched Livdelzi for primary biliary cholangitis in late 2024, representing entry into a new liver disease indication. Early commercial results have exceeded expectations, with European approval following in early 2025. Gilead has also been expanding its cell therapy manufacturing capabilities and working to make these personalized treatments available in community oncology settings rather than just major medical centers. Strategic partnerships have become increasingly important, with collaborations including Arcus Biosciences, Pionyr Immunotherapeutics, and others focused on advancing the company's oncology pipeline. The company has maintained disciplined expense management while investing heavily in R&D, currently running 54 clinical programs across its therapeutic areas. Looking ahead, Gilead is developing multiple long-acting HIV treatment options that could provide 3-6 month dosing intervals, potentially revolutionizing HIV care.
GILD company profile · for informational purposes only — not investment advice.
Track GILD with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free